MilliporeSigma and 10x Genomics announced on Wednesday a collaboration on single-cell CRISPR screening workflows.
The workflows will combine MilliporeSigma's CRISPR genome editing reagents with 10x's Feature Barcode assay to enable single-cell screens for changes in gene expression that result from those edits.
"There has been and continues to be extensive interaction between our R&D teams to test and validate our CRISPR vectors with compatibility on the 10x Genomics platform," a MilliporeSigma spokesperson wrote in an email. The firms also have a commercial arrangement under which they plan to put on joint webinars. Financial and other details of the collaboration were not disclosed.
The collaboration will take place under 10x's Compatible Partnership Program. MilliporeSigma is the life sciences business of Germany's Merck KGaA and operates under that name in the US, Canada, and Puerto Rico.
Andrew Bulpin, head of process solutions at MilliporeSigma, said in a statement that the combined technologies will enable "the identification of novel molecular therapeutic targets and accelerate drug discovery in immuno-oncology, autoimmunity, neurodegeneration and other human diseases."
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.